Study of NK012 in Patients With Refractory Solid Tumors

NCT ID: NCT00542958

Last Updated: 2019-10-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 39 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-03-31
• Study Completion Date: 2011-12-31

Brief Summary

The purpose of this study is to determine whether NK012 is safe and effective in the treatment of refractory solid tumors

Detailed Description

This is a Phase I dose-escalation study of the intravenous administration of NK012 in patients with refractory solid tumors. Patients will receive NK012 as an intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (3 weeks) per cycle. Two patient populations will be evaluated separately: patients with UGT1A1*28 genotype homozygous wild type (wt/wt) and heterozygous (wt/*28) variants as one group, and patients with UGT1A1*28 homozygous variant (*28/*28) as another group.

Conditions

Cancer

Study Design

• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

NK012

This is a Phase I dose-escalation study of the intravenous administration of NK012 in patients with refractory solid tumors. Patients will receive NK012 as an intravenous infusion over 30 minutes on Day 1 followed by a 20-day observation period for a total of 21 days (3 weeks) per cycle. Two patient populations will be evaluated separately: patients with UGT1A1*28 genotype homozygous wild type (wt/wt) and heterozygous (wt/*28) variants as one group, and patients with UGT1A1*28 homozygous variant (*28/*28) as another group. Dose-escalation in each patient population will proceed according to the predefined dose level.

For UGT1A1*28 (wt/wt and wt/*28) patients, at least 3 evaluable patients will be treated at each dose level.

UGT1A1 homozygous (*28/*28) patients will be treated at 50% of the current dose level.

Patients will receive up to 6 cycles of NK012, unless they experience unacceptable toxicity or disease progression, requiring withdrawal from the study.

Group Type: EXPERIMENTAL

NK012

Intervention Type: DRUG

9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion

Interventions

NK012

9.0, 12.0, 16.0, 21.0, 28.0 mg/m\^2, and to be determined. Intravenous infusion

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Histologically confirmed malignant solid tumor for which there are no known regimens or protocol treatments of higher efficacy or priority
• Failed conventional therapy for the cancer or have a malignancy for which a conventional therapy does not exist
• Recovered from all acute adverse effects of prior therapies, excluding alopecia (hair loss)
• Life expectancy of at least 12 weeks and an EOCG performance status of 0 or 1
• 18 years of age or older
• Adequate kidney, liver, and bone marrow function
• Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria

• Have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or have not recovered from adverse effects due to agents administered more than 4 weeks earlier
• Receiving any other investigational agent
• History of brain metastases or spinal cord compression, unless irradiated a minimum of 4 weeks before study entry and stable without requirement for corticosteroids for > 1 week
• History of allergic reactions attributed to compounds of similar chemical composition to NK012
• Concurrent serious infections (i.e., requiring an intravenous antibiotic)
• Pregnant women or women of childbearing potential who are not using methods to avoid pregnancy; a negative pregnancy test (urine or serum) must be documented at baseline and before every NK012 administration for women of childbearing potential; no breast-feeding while on study
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, unstable angina pectoris or psychiatric illness/social situations that would limit compliance with study requirements
• Significant cardiac disease
• History of serious ventricular arrhythmia
• Positive for anti-HbsAg, anti-HCV, anti-HIV, or anti-syphilis antibodies

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Nippon Kayaku Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Howard A. Burris, III, MD

Role: PRINCIPAL_INVESTIGATOR

SCRI Development Innovations, LLC

Locations

Sarah Cannon Research Institute

Nashville, Tennessee, United States

Countries

United States

Other Identifiers

N06-10089

Identifier Type: -

Identifier Source: org_study_id